bemethyl and Pyoderma

bemethyl has been researched along with Pyoderma* in 1 studies

Other Studies

1 other study(ies) available for bemethyl and Pyoderma

Article	Year
[A new approach to the therapy of pyoderma in servicemen: the use of the actoprotector bemitil]. Voenno-meditsinskii zhurnal, 1998, Volume: 319, Issue:5 At 51 men at the age from 20 till 30, sick with pyodermatitis, the clinical-immunological aspects and efficiency of-actoprotector, capable to support motor activity and human performance in the extreme environments. Bemitil has appeared more effective in comparison with conventional therapy: by general and combined application the parameters of immunity have been normalized statistically authentically, and at outside application-the places of damage were cleared faster, disappeared painfulness, hyperemia, edema, terms of staying in the hospital were reduced. The clinical recovery was in 86.3 +/- 4.8% of the patients, while effectiveness from conventional means was 62.1 +/- 6.8%. Topics: Adjuvants, Immunologic; Adult; Antibody Formation; Benzimidazoles; Chronic Disease; Drug Evaluation; Humans; Immunity, Cellular; Military Personnel; Ointments; Pyoderma; Recurrence; Russia; Tablets	1998

Article

Year

[A new approach to the therapy of pyoderma in servicemen: the use of the actoprotector bemitil].

Voenno-meditsinskii zhurnal, 1998, Volume: 319, Issue:5

At 51 men at the age from 20 till 30, sick with pyodermatitis, the clinical-immunological aspects and efficiency of-actoprotector, capable to support motor activity and human performance in the extreme environments. Bemitil has appeared more effective in comparison with conventional therapy: by general and combined application the parameters of immunity have been normalized statistically authentically, and at outside application-the places of damage were cleared faster, disappeared painfulness, hyperemia, edema, terms of staying in the hospital were reduced. The clinical recovery was in 86.3 +/- 4.8% of the patients, while effectiveness from conventional means was 62.1 +/- 6.8%.

Topics: Adjuvants, Immunologic; Adult; Antibody Formation; Benzimidazoles; Chronic Disease; Drug Evaluation; Humans; Immunity, Cellular; Military Personnel; Ointments; Pyoderma; Recurrence; Russia; Tablets

1998